Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1981 Feb 28;282(6265):692–695. doi: 10.1136/bmj.282.6265.692

Long survival in acute myelogenous leukaemia: an international collaborative study.

J A Whittaker, P Reizenstein, S T Callender, G G Cornwell, I W Delamore, R P Gale, M Gobbi, P Jacobs, B Lantz, A T Maiolo, J K Rees, E J Van Slyck, H V Van
PMCID: PMC1504540  PMID: 6781618

Abstract

A group of 82 adult patients with acute myelogenous leukaemia had survived in continuous first remission for more than three years was studied. These long-surviving patients were being treated at 12 referral centres in Europe and the USA, and they were compared with other patients with acute myelogenous leukaemia from 10 of these centres. There was no clear difference in the amount of induction chemotherapy or the time taken to achieve remission. Immunotherapy was not found to improve chances of long-term survival. The 82 patients were also compared with a group of 115 patients who had no appreciable difference in the number of blood or marrow myeloblasts between these two groups at presentation, but the long survivors had significantly higher initial platelet counts and were slightly younger. The long survivors also tended to have a lower total white cell count at presentation and lower granulocyte counts; there was no obvious explanation for these differences. Eight of the 82 patients relapsed from three to four years after remission and two (of 69 patients) after four to five year. Thereafter relapse was rare, and it seems likely that some of the 40 patients who have survived for five years or more are cured.

Full text

PDF
692

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976 Aug;33(4):451–458. doi: 10.1111/j.1365-2141.1976.tb03563.x. [DOI] [PubMed] [Google Scholar]
  2. Brouet J. C., Seligmann M. The immunological classification of acute lymphoblastic leukemias. Cancer. 1978 Aug;42(2 Suppl):817–827. doi: 10.1002/1097-0142(197808)42:2+<817::aid-cncr2820420703>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  3. Dow L. W., Borella L., Sen L., Aur R. J., George S. L., Mauer A. M., Simone J. V. Initial prognostic factors and lymphoblast-erythrocyte rosette formation in 109 children with acute lymphoblastic leukemia. Blood. 1977 Oct;50(4):671–682. [PubMed] [Google Scholar]
  4. Fiere D., Martin C., Vu Van H., Coiffier B., Felman P., Bryon P. A., Gentilhomme O., Revol L. Leucémies myéloïdes aiguës. Survie supérieure à 3 ans chez 16 malades. Nouv Presse Med. 1978 Mar 18;7(11):899–902. [PubMed] [Google Scholar]
  5. Freireich E. J., Keating M. J., Gehan E. A., McCredie K. B., Bodey G. P., Smith T. Therapy of acute myelogeneous leukemia. Cancer. 1978 Aug;42(2 Suppl):874–882. doi: 10.1002/1097-0142(197808)42:2+<874::aid-cncr2820420709>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  6. Gale R. P., Cline M. J. High remission-induction rate in acute myeloid leukaemia. Lancet. 1977 Mar 5;1(8010):497–499. doi: 10.1016/s0140-6736(77)91366-6. [DOI] [PubMed] [Google Scholar]
  7. Greaves M. F., Brown G., Rapson N. T., Lister T. A. Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol. 1975 May;4(1):67–84. doi: 10.1016/0090-1229(75)90041-0. [DOI] [PubMed] [Google Scholar]
  8. Jacquillat C., Weil M., Gemon M. F., Izrael V., Schaison G., Auclerc G., Ablin A. R., Flandrin G., Tanzer J., Bussel A. Evaluation of 216 four-year survivors of acute leukemia. Cancer. 1973 Aug;32(2):286–293. doi: 10.1002/1097-0142(197308)32:2<286::aid-cncr2820320202>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  9. Kawashima K., Suzuki H., Yamada K., Kato Y., Watanabe E., Morishima Y., Takeyama H., Kobayashi M. Long-term survival in acute leukemia in Japan. A study of 304 cases. Cancer. 1980 Apr 15;45(8):2181–2187. doi: 10.1002/1097-0142(19800415)45:8<2181::aid-cncr2820450829>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  10. Rees J. K., Sandler R. M., Challener J., Hayhoe F. G. Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT. Br J Cancer. 1977 Dec;36(6):770–776. doi: 10.1038/bjc.1977.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Whittaker J. A., Bailey-Wood R., Hutchins S. Active immunotherapy for the treatment of acute myelogenous leukaemia: report of two controlled trials. Br J Haematol. 1980 Jul;45(3):389–400. doi: 10.1111/j.1365-2141.1980.tb07159.x. [DOI] [PubMed] [Google Scholar]
  12. Zuhrie S. R., Harris R., Freeman C. B., MacIver J. E., Geary C. G., Delamore I. W., Tooth J. A. Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia. Br J Cancer. 1980 Mar;41(3):372–377. doi: 10.1038/bjc.1980.60. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES